Innovative Eyewear, Inc. (NASDAQ:LUCY – Get Free Report) major shareholder Vladimir Galkin sold 258,483 shares of the company’s stock in a transaction that occurred on Tuesday, September 17th. The stock was sold at an average price of $7.27, for a total value of $1,879,171.41. Following the transaction, the insider now directly owns 420,000 shares of the company’s stock, valued at $3,053,400. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
Innovative Eyewear Stock Performance
LUCY traded up $1.15 on Tuesday, reaching $10.20. 220,424 shares of the company’s stock were exchanged, compared to its average volume of 1,204,185. The stock’s fifty day moving average price is $5.06 and its 200-day moving average price is $6.55. Innovative Eyewear, Inc. has a twelve month low of $3.26 and a twelve month high of $27.20.
Innovative Eyewear (NASDAQ:LUCY – Get Free Report) last posted its quarterly earnings results on Monday, August 12th. The company reported ($1.87) EPS for the quarter. Innovative Eyewear had a negative return on equity of 128.67% and a negative net margin of 513.65%. The firm had revenue of $0.31 million for the quarter.
About Innovative Eyewear
Innovative Eyewear, Inc develops and sells smart eyeglasses and sunglasses. The company's flagship product is Lucyd Lyte glasses that enable the wearer to listen to music, take and make calls, and use voice assistants to perform various smartphone tasks hands-free. It also offers Vyrb, a social media application that enables the user to receive and send posts through Lucyd Lyte smart glasses with voice.
Read More
- Five stocks we like better than Innovative Eyewear
- Pros And Cons Of Monthly Dividend Stocks
- Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- What is the Dow Jones Industrial Average (DJIA)?
- Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
- What is the S&P/TSX Index?
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Receive News & Ratings for Innovative Eyewear Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innovative Eyewear and related companies with MarketBeat.com's FREE daily email newsletter.